DISEASE MANAGEMENT
Imiglucerase
What is imiglucerase?
Imiglucerase is an intravenous enzyme replacement therapy for Gaucher disease.
INTRODUCING
Velaglucerase alfa
The introduction of enzyme replacement therapy and substrate reduction therapy has enhanced the management of Gaucher disease.
Velaglucerase alfa is an intravenous enzyme replacement therapy for Gaucher disease.1 The mechanism of action of velaglucerase alfa is presented in Figure 1. For further information on velaglucerase alfa, please consult your local prescribing information.
Figure 1.
Mechanism of action of velaglucerase alfa1,3
C-ANPROM/INT//7568; Date of preparation: September 2020
- Shire Pharmaceuticals Ltd. VPRIV® EU Summary of Product Characteristics. Last updated August 2020.
- Stirnemann J, Belmatoug N, Camou F, et al. A review of Gaucher disease pathophysiology, clinical presentation and treatments. Int J Mol Sci 2017; 18: 441.
DISEASE MANAGEMENT
Taliglucerase alfa
What is taliglucerase alfa?
Taliglucerase alfa is an intravenous enzyme replacement therapy for Gaucher disease.
DISEASE MANAGEMENT
Enzyme replacement therapy
What enzyme replacement therapies are available for Gaucher disease?
Three long-term enzyme replacement therapies are available for patients with Gaucher disease: imiglucerase, velaglucerase alfa and taliglucerase alfa.
Register
Registration gives the benefit of site update emails and additional information on new education materials and events